(2pyridyldithio)peg2boc

(2-Pyridyldithio)-PEG2-Boc is a polyethylene glycol-based PROTAC linker used in the synthesis of PROTACs [1].

dMCL1-2 is a potent and selective myeloid leukemia 1 (MCL1) degrading agent based on PROTAC, binding to MCL1 with a KD of 30 nM and activating the apoptosis mechanism by degrading MCL1.

5-Ethynyl-2'-deoxyuridine (EdU) is a nucleoside analog of thymidine used to monitor de novo DNA synthesis through click chemistry and serves as an alkyl chain-based PROTAC linker for synthesizing PROTACs.

1,2-Bis(2-iodoethoxy)ethane is a PEG-based PROTAC linker used in the synthesis of MT802 and SJF620, which are potent PROTAC BTK degraders with DC50s of 1 nM and 7.9 nM, respectively [1].

2-Phthalimidehydroxy-acetic acid is an alkyl chain-based PROTAC linker utilized in PROTAC synthesis.

PROTAC ERRα ligand 2 is an inverse agonist for the estrogen-related receptor α (ERRα) with an IC50 of 5.67 nM.

TSPO ligand-2 (Carbonic acid) is a ligand of AUTAC1 which contains a p-fluorobenzylguanine and a Fumagillol moiety.

Hydroxy-PEG4-(CH2)2-Boc is an uncleavable ADC linker utilized in the synthesis of antibody-drug conjugates (ADCs) and can also be employed in the synthesis of PROTAC.

Compound 72-1, also known as BCL-xL BCL-2 ligand 1, serves as a ligand for BCL-xL and BCL-2 proteins. It can be tethered to an E3 ligase via a linker, facilitating the formation of PROTACs [1] [2].

VEGFR-2-IN-39 (PROTAC-5), a PROTAC that targets VEGFR-2 with an IC 50 of 208.6 nM, demonstrates low toxicity. It effectively inhibits the proliferation of EA.hy926, a type of HUVEC, in a concentration-dependent manner, achieving an IC 50 value of 38.65 µM [1].

PROTAC BRD4 Ligand-2 Hydrochloride serves as a ligand targeting the BRD4 protein, specifically designed for use with PROTAC CFT-2718.

YX-2-107 is a selective and potent CDK6-degrading PROTAC with an IC50 value of 4.4 nM.YX-2-107 inhibits RB phosphorylation and FOXM1 expression in vitro, and inhibits the development of Ph+ ALL in rats.YX-2-107 can be used for the prophylaxis and treatment of Ph chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). YX-2-107 can be used for the prevention and treatment of Ph chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

PROTAC STAT3 degrader-2 is a selective and effective PROTAC degrader of the STAT3 protein, exhibiting a DC50 of 3.54 μM in Molm-16 cells. It holds potential for cancer research [1].

N-Boc-PEG-t-butyl ester is a PEG-based linker for PROTACs, joining two essential ligands to facilitate selective protein degradation via the ubiquitin-proteasome system within cells.

PROTAC Bcl-xL degrader-2, based on von Hippel-Lindau ligand, is a potent degrader of Bcl-xL (a Bcl-2 family member), demonstrating an IC 50 of 0.6 nM.

PROTAC EGFR degrader 2 is a potent compound with an IC50 of 4.0 nM, demonstrating strong antiproliferative activity, and a DC50 of 36.51 nM, indicating robust EGFR degradation activity. It is suitable for synthesizing nitroreductase (NTR)-responsive PROTACs [1].

RIPK2-IN-2 (example 25) is a RIP2 kinase PROTAC inhibitor that effectively blocks RIP2-dependent pro-inflammatory signaling and regulates RIP2 kinase activity in autoinflammatory diseases [1].

PROTAC VEGFR-2 Degrader-1 (PROTAC-1), a specific degrader of PROTAC VEGFR-2, demonstrates minimal inhibition of VEGFR-2 (IC50 > 1 μM) and exhibits low anti-proliferative effects on EA.hy926 cells (IC50 > 100 μM) [1].

PROTAC VEGFR-2 degrader-2 (PROTAC-4), a specific degrader of VEGFR-2, demonstrates minimal inhibition of VEGFR-2 (IC50 > 1 μM) and low anti-proliferative activity towards EA.hy926 cells (IC50 > 100 μM) [1].

(R)-Azetidine-2-carboxylic acid, with catalog number T66331 and CAS number 7729-30-8, is a valuable organic compound for life sciences research.

Bis (2-bromoethyl) ether, an alkyl chain-derived PROTAC linker, facilitates the synthesis of PROTACs.

GID4 Ligand 2 (compound 67) is a selective binder for GID4 with an IC50 of 18.9 μM and a Kd of 17 μM, and can be used for the synthesis of PROTACs [1].

Bis-Tos-(2-hydroxyethyl disulfide) is a cleavable linker used in the synthesis of antibody-drug conjugates (ADCs) [1].

DBCO-(PEG2-Val-Cit-PAB)2 is a dual-cleavable linker used in antibody-drug conjugates (ADCs).

6-O-2-Propyn-1-yl-D-galactose functions as an irreversible glycolinker, facilitating the attachment of cytotoxic drugs for applications in antibody-drug conjugation (ADC).

PROTAC BET-binding moiety 2 is an inhibitor of the BET bromodomain.

PROTAC ERRα Degrader-2 is a compound consisting of an MDM2 ligand binding group, a linker, and an estrogen-related receptor alpha (ERRα) binding group. This compound is designed to specifically degrade estrogen-related receptor alpha (ERRα), acting as an ERRα degrader[1].

4-Methyl-4-(pyridin-2-yldisulfanyl)pentanoic acid is a cleavable linker compound used in the synthesis of antibody-drug conjugates (ADCs) [1].

PEG6-(CH2CO2H)2 is a symmetric PEG PROTAC linker.

PROTAC MDM2 Degrader-2, designed using PROTAC technology, functions as a MDM2 degrader. It consists of a highly potent MDM2 inhibitor, a linker, and the MDM2 ligand for E3 ubiquitin ligase, facilitating the degradation of MDM2[1].

cIAP1 Ligand-Linker Conjugates 2 is a chemical compound that combines an IAP ligand for the E3 ubiquitin ligase with a PROTAC linker. This compound is particularly useful in the design of SNIPERs [1].

(2-Pyridyldithio)-PEG4-alcohol, a PEG-based PROTAC linker, is used for the synthesis of PROTACs[1].

Boc-NH-PEG-amine (MW 2000) is a polyethylene glycol (PEG) linker utilized in PROTAC synthesis[1].

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthesized E3 ligase ligand-linker, incorporating a cereblon ligand based on Thalidomide and a 3-unit PEG linker, specifically designed for PROTAC technology applications.

SNIPER(TACC3)-2 targets TACC3 protein degradation via the ubiquitin-proteasome pathway. It induces cancer cell death.

Mpro ligand 2 (Compound 8) serves as the target protein ligand for PROTAC SARS-CoV-2 Mpro degrader-3.

PROTAC ATR degrader-2 (Compound 8i) serves as a PROTAC degrader targeting ATR, effectively degrading it in acute myeloid leukemia (AML) cell lines MV-4-11 and MOLM-13, with DC50 values of 22.9 and 34.5 nM, respectively. This compound induces apoptosis and inhibits the proliferation of AML cells. Additionally, PROTAC ATR degrader-2 demonstrates favorable pharmacokinetic properties and potent antitumor activity in a mouse model of AML. (Pink: ATR ligand; Blue: E3 ligase ligand Lenalidomide; Black: linker) [1]

NJH-2-030 is a covalent recruiting compound utilized in targeted protein degradation applications for FEM1B.

PROTAC TG2 degrader-2 (compound 7) is a selective competitive degrader of Transglutaminase 2 (TG2) with a dissociation constant (Kd) greater than 100 μM. It inhibits cell migration and reduces TG2 levels in ovarian cancer cells, making it a valuable tool for ovarian cancer research [1].

PROTAC PTPN2 degrader-2 (example 187B) TFA is a potent Protein Tyrosine Phosphatase Non-receptor Type 2 (PTPN2) degrader with potential applications in cancer and metabolic disease research [1].

PROTAC BRD9 Degrader-2 is a bifunctional compound engineered for the targeted degradation of BRD9 (Bromodomain containing 9) in cancer research applications.

PROTAC Axl Degrader 2, a potent and selective PROTAC Axl degrader, demonstrates an IC50 of 1.61 µM. It exhibits anti-proliferative and anti-migratory activities in vitro and induces mehuosis [1].

PROTAC IRAK4 Degrader-2 (Compound 9) is a PROTAC-based degrader that potently reduces IRAK4 levels, achieving a DC50 of 151 nM in peripheral blood mononuclear cells (PBMCs). It also notably decreases IRAK4 protein levels with a DC50 of 36 nM in the same cell type and inhibits several cytokines in PBMCs [1].

SHP2 protein degrader-2 (SHP2-D26), a PROTAC degrader targeting the SHP2 protein, effectively reduces its expression across various cancer cell types [1].

Cbl-b-IN-2 is an orally active biological compound that inhibits the E3 enzyme Casitas b lineage lymphoma proto-oncogene b (Cbl-b) in the ubiquitin proteasome pathway and can be used in the study of diseases that modulate the immune system and are susceptible to regulation by the immune system. Cbl-b-IN-2 can also be used in cancer research alone or in combination with one or more immune checkpoint inhibitors, antitumour agents and radiopharmaceuticals.

PROTAC BET degrader-2 is a highly potent degrader of Bromodomain and Extra-Terminal (BET) proteins, with an IC50 of 9.6 nM.